Dec 17 (Reuters) - Imugene Ltd IMU.AX :
* IMUGENE MEETS ENDPOINTS IN PHASE 1B GASTRIC CANCER IMMUNO-ONCOLOGY TRIAL
* NO SAFETY ISSUES WERE REPORTED AND HER-VAXX WAS FOUND TO BE WELL TOLERATED
Dec 17 (Reuters) - Imugene Ltd IMU.AX :
* IMUGENE MEETS ENDPOINTS IN PHASE 1B GASTRIC CANCER IMMUNO-ONCOLOGY TRIAL
* NO SAFETY ISSUES WERE REPORTED AND HER-VAXX WAS FOUND TO BE WELL TOLERATED